Related Experiment Video
Updated: Mar 13, 2026
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.9K
Diffuse Large B-cell Lymphoma during Corticosteroid Therapy for TAFRO Syndrome
Eiko Ohya1, Minoru Mizutani, Haruna Sakaguchi
1Department of Internal Medicine, Matsusaka Chuo General Hospital, Japan.
Internal Medicine (Tokyo, Japan)
|October 12, 2016
Summary
Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction and organomegaly (TAFRO) syndrome, a Castleman
Area of Science:
- Hematology
- Oncology
- Pathology
Background:
- TAFRO syndrome is a rare variant of Castleman's disease.
- It presents with a distinct set of symptoms including thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly.
- Diagnosis and treatment of TAFRO syndrome are complex and evolving.
Observation:
- A 73-year-old male patient was diagnosed with TAFRO syndrome.
- Initial treatment with corticosteroids led to symptom improvement.
- Recurrence of lymphadenopathy was observed during corticosteroid tapering.
Findings:
- Histological examination revealed diffuse large B-cell lymphoma in abdominal lymph nodes.
- The patient achieved complete remission after R-CHOP chemotherapy.
- This case highlights the potential development of lymphoma during TAFRO syndrome treatment.
Implications:
- Suggests a possible association between TAFRO syndrome and diffuse large B-cell lymphoma.
- Underscores the importance of vigilant monitoring for secondary malignancies in TAFRO syndrome patients.
- May inform future diagnostic and therapeutic strategies for TAFRO syndrome and associated lymphomas.
More Related Videos
Related Concept Videos
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
593
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
593
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
636
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
636
01:29Pulmonary Tuberculosis I
1.2K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.2K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
693
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
693